Format

Send to

Choose Destination
Future Oncol. 2019 Jun;15(17):1989-1995. doi: 10.2217/fon-2019-0001. Epub 2019 Jun 7.

Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients.

Author information

1
Department of Internal Medicine, Section of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA.

Abstract

Aim: This study evaluated the overall survival (OS) of older patients (≥60 years) with acute myeloid leukemia based on the intensity of treatment. Methods: This single center, retrospective study included 211 patients diagnosed between 2000 and 2016, who received 10-day decitabine, low-intensity therapy or high-intensity therapy. Cox regression examined the impact of therapy on OS. Results: Younger patients were more likely to receive high-intensity therapy. Patients who received low-intensity therapy had worse OS compared with high-intensity therapy (median OS: 1.2 vs 8.5 months; p < 0.01). OS was similar with 10-day decitabine (median OS of 6.3 months) compared with either low-intensity therapy or high-intensity therapy. Conclusion: Ten-day decitabine is an effective alternative in older patients with newly diagnosed acute myeloid leukemia.

KEYWORDS:

10-day decitabine; acute myeloid leukemia; frail patients; hypomethylating agents; older adults; overall survival

PMID:
31170814
DOI:
10.2217/fon-2019-0001

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center